Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
Stuart D. Cook(Rutgers, The State University of New Jersey), Elke Sylvester(Merck KGaA, Darmstadt (Germany)), Gavin Giovannoni(Queen Mary University of London), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Christine Hicking(Merck KGaA, Darmstadt (Germany)), Axel Nolting(Merck KGaA, Darmstadt (Germany)), Giancarlo Comi(Vita-Salute San Raffaele University), Andrew Galazka(Merck KGaA, Darmstadt (Germany)), Thomas Leist(Thomas Jefferson University)
Cited by 122
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k